Access to COVID-19 Tools Accelerator (ACT-A)

2 over-riding objectives

• accelerate the development of new diagnostics, treatments & vaccines

• achieve equitable global access to all COVID-19 tools
10 months into the pandemic, >46 M people have already been infected & 1.2 M people have died

Northern hemisphere enters flu season already suffering 2\textsuperscript{nd} wave.

- rate of new cases doubled in Oct, reaching 500,000/day
- Europe enters 2\textsuperscript{nd} lockdown

Source: WHO Dashboard as of 1\textsuperscript{st} Nov 2020
2 months ago, ACT-Accelerator moved into scale-up
Scale-up Plan & Investment Case, Released 25 September 2020

Status Report & Plan provides an overview of ACT-Accelerator’s goal, approach, achievements to date & near-term priorities. Link

Investment Case provides an economic rationale for investing in ACT-A as a global, integrated, ‘end-to-end’ solution. Link
ACT-A has already **hit key landmarks in its scale-up phase** (examples at 4 Nov 2020)

- **new Rapid Tests** approved, with volume & price guarantees for LICs/LMICs (120m tests @ $3-5/unit over 6 months)
- **1st life-saving therapy** in rollout (Dexamethasone) with 3 M doses for LICs; **monoclonal antibodies** in evaluation for LICs
- **COVAX Facility ‘in business’ with 186+ economies** (>90% of world population); dynamic vaccine portfolio
- **Equitable Allocation Framework & COVAX Allocation Mechanism** established
Halfway through ACT-A’s scale-up phase, **4 major trends** are driving sharper priorities & updated funding needs

- **Deeper understanding of the evolving product portfolio**
- **Imminent product ‘read-outs’** could impact end of pandemic
- **Equitable access threatened by lack of funding & in-country capacities**
- **New evidence that multilateralism accelerates global recovery**

**Weekly Number of cases by region**, in million

- **Read-outs & scale-up**
- **Impact**

- **Today**
  - 3.3 (illustrative)

**Pessimistic**

**Optimistic**
ACT-A is helping to save lives with these tools & accelerate other game changing products in the coming months.

**Increasing disease severity**

- Prevent
- Protect
- Treat

**Pre ACT-A**
- PPE
- PCR
- Oxygen

**by November**
- PPE
- RDTs
- PCR
- Dexa
- Oxygen

**by March 2021**
- PPE
- RDTs
- PCR
- mAbs
- Dexamethasone
- Vaccines

XXX New tool  ACTaccelerator ACCESS TO COVID-19 TOOLS

PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies
But **access to these critical tools differs widely across countries** & could worsen without urgent financial & political action

**Prevent**
- **PPE use**

**Protect**
- **Vaccine deals**

**Test**
- **RDT/PCR use**

**Treat**
- **Dexa use**

---

**High Income**
- Prevent: 
- Protect: 
- Test: 
- Treat: 

**Low income**
- Prevent: 
- Protect: 
- Test: 
- Treat: 

---

**Access level of tools**
- Rare
- Common

PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies
ACT-A aims to **start changing the fundamental dynamic of the pandemic by March**

**Diagnostics**
Expanded testing **globally:** with immediate increase in the number & volume of high-quality RDTs and facilitating their use

**Therapeutics**
Wider availability of treatments to save lives: by accelerated use of Dexamethasone & oxygen and secured production capacities for mAbs

**Vaccines**
Full vaccination readiness: with doses secured for global rollout to +20% of population; further R&D, tech transfer & capacity scale-out

**Health systems connector**
Best practice for delivering COVID-19 tools established and in roll out: with rapid assessments, integrated delivery plans, large scale PPE use and key systems investments
US$4.5 B is required urgently for this near-term ACT Accelerator scale-up and impact

**Evolution of ACT-A funding need —$US B**

<table>
<thead>
<tr>
<th>The ACT Accelerator Budget</th>
<th>Pledges, cost adjusts &amp; COVAX self financing</th>
<th>Urgent ACT-A financing gap</th>
<th>Balance of ACT-A 2021 financing gap</th>
</tr>
</thead>
<tbody>
<tr>
<td>38.1</td>
<td>9.7</td>
<td>4.5</td>
<td>23.9</td>
</tr>
<tr>
<td>6.0</td>
<td>1.1</td>
<td>4.2</td>
<td>1.7</td>
</tr>
<tr>
<td>7.2</td>
<td>8.1</td>
<td>5.4</td>
<td>0.1</td>
</tr>
<tr>
<td>15.9</td>
<td>0.1</td>
<td>6.8</td>
<td></td>
</tr>
<tr>
<td>9.0</td>
<td></td>
<td>7.5</td>
<td></td>
</tr>
</tbody>
</table>

**Urgent ACT-A financing gap per Pillar —$US B**

<table>
<thead>
<tr>
<th>Pillar</th>
<th>Gap (US$ B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostics</td>
<td>1.1</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>0.75</td>
</tr>
<tr>
<td>Vaccines</td>
<td>1.0</td>
</tr>
<tr>
<td>HS Connector</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>4.5</strong></td>
</tr>
</tbody>
</table>

1. incl. US$ 0.1 B by Gavi for Vaccine Procurement/Delivery; 2. COVAX Facility manufacturing & procurement costs financed by self-financing participants (SFP) [List of SFPs](#)
"...if medical solutions can be made available faster and more widely relative to our baseline, it could lead to a cumulative increase in global income of almost $9 trillion by end-2025"

IMF World Economic Outlook, October 2020

Addressing ACT-A’s urgent needs = only 1 day of that income and would save countless lives
On 2 November, the ACT-A Facilitation Council discussed the evolving priorities & urgent financing needs

Programme Summary

Co-Chairs: MoH, South Africa & Min Int’l Dev, Norway
Participation: 165 delegates & invitees online

Session I – Access to ACT-A’s New & Emerging Tools
• Keynote: Sir Witty, WHO Special Envoy
• Panel: Dr Nsanzimana (Rwanda), Sir Farrar (Wellcome)
• Speakers: St Kitts & Nevis, Singapore, Japan, China, Republic of Korea, Russia, Vietnam, Spain, Saudi Arabia

Session II – Urgent Macroeconomic Case for ACT-A
• Keynote: Lord Jim O’Neill & Petya Koeva (IMF)
• Panel: Ms Murthi (World Bank), J Denton (ICC), CSO
• Speakers: Canada, India, Brazil, CSO

Closing Call to Action
• France & Saudi Arabia (Paris Peace Forum & G20)
• UK & Italy (incoming G7 & G20)

Some Highlights

‘Midway into the scale-up phase, ACT-A’s promise of equitable access is under threat due to serious financing gaps...’
Minister Ulstein, Norway

‘Every country will need to play a part in financing an end to this crisis. Every leader has political choices to make’.
Minister Mkhize, South Africa

‘The time for talking is over. There is an exit strategy through WHO & ACT-A.’
Jeremy Farrar, Wellcome

‘ACT-A needs < 1/10 of 1% of global GDP; this is the easiest decision for world leaders’.
Lord Jim O’Neill
Next Steps

• Incorporate final comments and publish *ACT-A Urgent Priorities & Financing Gaps (at 9 Nov 2020)*

• Finalize and issue the *ACT-A Facilitation Council Co-Chairs Summary & Next Steps*

• Intensify the ACT-A Advocacy Campaign, particularly through Paris Peace Forum (11-13 Nov) & G20 Leaders Summit (21-22 Nov)